Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253

Status Recruiting

Clinical Trial Summary

This is a prospective randomized controlled study. investigators will randomly assign patients to the indocanine green (ICG) group and control (CL)group to compare the differences of lymph nodes dissection in station 253 between the two groups.

Clinical Trial Description

ICG is a registered and FDA-approved non-specific fluorescent probe for optical imaging in clinical settings. The properties of ICG ,which is a water-soluble amphiphilic molecule with a molecular weight of 775 Dalton and a hydrodynamic diameter of 1.2nm ,render it an excellent lymphatic contrast agents if injected into the lymphatic system. ICG near-infrared(NIR) fluorescent imaging has achieved satisfactory results in the localization of sentinel lymph nodes in patients with breast cancer,non-small cell lung cancer,and gastric cancer. Liang et al have suggested that 253 lymph nodes dissection in rectal cancer is technically demanding ,and that learning curve for laparoscopic 253 lymph nodes dissection requires minimally 20 procedures. Currently,it was still controversial about 253 lymph nodes dissection in rectal cancer surgery. However, lymph node involvement is a major prognostic factor for survival after rectal cancer surgery. Therefore, it is necessary to harvest more station 253 nodes for the better long-term survival and the more precise staging. In this study, investigators will randomly assign patients to the indocanine green (ICG) group and control (CL)group. Number of harvested station 253 lymph nodes, number of positive station 253 lymph nodes, will be evaluated and compared. Investigators will also evaluate patients, operative time, blood loss, post-operative hospital stay and complications. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04848311
Study type	Interventional
Source	Nanfang Hospital of Southern Medical University
Contact	Jun Yan, M.D,Ph.D
Phone	13825066546
Email	yanjunfudan@163.com
Status	Recruiting
Phase	N/A
Start date	May 1, 2021
Completion date	May 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01227239` - Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting	Phase 1/Phase 2
Recruiting	`NCT01459328` - Resource-Sparing Curative Treatment for Rectal Cancer	Phase 3
Recruiting	`NCT04078828` - PR in Endoscopic LAR for Rectal Cancer	N/A
Terminated	`NCT02797405` - Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay	N/A
Completed	`NCT01751516` - PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
Terminated	`NCT01111292` - Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia	Phase 1/Phase 2
Completed	`NCT00682786` - Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma	Phase 2
Completed	`NCT02000050` - Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)	Phase 2
Recruiting	`NCT04749108` - Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma	Phase 2/Phase 3
Active, not recruiting	`NCT01696981` - Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)	N/A
Active, not recruiting	`NCT01899547` - Laparoscopy-Assisted Surgery for Carcinoma of the Low Rectum	N/A
Completed	`NCT01333709` - Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma	Phase 2
Not yet recruiting	`NCT02770911` - Laparoscopic Anterior Resection With or Without "Dog Ear" Double-stapled Anastomosis for Rectal Cancer	Phase 3
Active, not recruiting	`NCT02432963` - Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy	Phase 1
Active, not recruiting	`NCT04505553` - Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer	Phase 2
Completed	`NCT01372007` - Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma	Phase 3
Active, not recruiting	`NCT02817126` - Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer	N/A
Completed	`NCT02551237` - Neoadjuvant Treatment for Advanced Rectal Carcinoma	Phase 3
Active, not recruiting	`NCT04713618` - Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy
Recruiting	`NCT02268006` - IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment	Phase 2